@article{3215036,
    title = "Histone Deacetylases and their Inhibitors in Colorectal Cancer Therapy: Current Evidence and Future Considerations.",
    author = "Garmpis, Nikolaos and Damaskos, Christos and Garmpi, Anna and Nonni, Afroditi and Georgakopoulou, Vasiliki E. and Antoniou, Efstathios and Schizas, Dimitrios and Sarantis, Panagiotis and Patsouras, Alexandros and Syllaios, Athanasios and Vallilas, Christos and Koustas, Evangelos and Kontzoglou, Konstantinos and Trakas, Nikolaos and Dimitroulis, Dimitrios",
    journal = "Current Medicinal Chemistry",
    year = "2021",
    issn = "0929-8673",
    doi = "10.2174/0929867328666210915105929",
    keywords = "*Inhibitors, *Histone, *HDAC, *Colorectal Cancer, *Deacetylase, *Epigenetics, *HDACI, *Targeted Therapy",
    abstract = "Colorectal cancer (CRC) comprises a heterogeneous group of gastrointestinal tract tumors. It is a multifactorial disease, and a plethora of distinct factors are  involved in its pathogenesis and pathophysiology. The development of CRC is not  limited to genetic changes, but epigenetic and environmental factors are also  involved. Among the epigenetic factors, histone deacetylases (HDACs), a group of  epigenetic enzymes that regulate gene expression, have been reported to be  over-expressed in CRC. HDACs and their inhibitors seem to play an important role in  the molecular pathophysiology of CRC. The aim of this review was to define the role  of HDAC inhibitors as potential anticancer agents against CRC."
}